<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067023</url>
  </required_header>
  <id_info>
    <org_study_id>QianfoshanH Z</org_study_id>
    <nct_id>NCT05067023</nct_id>
  </id_info>
  <brief_title>Evaluation for Benign and Malignant Pulmonary Ground-glass Nodules Based on MRI Dynamic Contrast Enhanced Imaging</brief_title>
  <official_title>Evaluation for Benign and Malignant Pulmonary Ground-glass Nodules Based on MRI Dynamic Contrast Enhanced Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qianfoshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qianfoshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Computed tomography (CT) is critical for the diagnosis of lung nodules as well as for&#xD;
      therapeutic management. Repeated CT examinations will raise the issue of the cumulative&#xD;
      radiation dose and subsequent risk of cancer, thus pushing the need for imaging techniques&#xD;
      using low or no radiation dose. Magnetic Resonance Imagery (MRI) with ultrashort echo time&#xD;
      (UTE) pulse sequences with high signal-to-noise and spatial resolution is a promising&#xD;
      alternative for lung nodules imaging.The purpose of the study is to evaluate the value of&#xD;
      dynamic contrast-enhanced MR imaging (DCE-MRI) to discriminate of malignant from benign&#xD;
      lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Computed tomography (CT) is critical for the diagnosis of lung nodules as well as for&#xD;
      therapeutic management. Repeated CT examinations will raise the issue of the cumulative&#xD;
      radiation dose and subsequent risk of cancer, thus pushing the need for imaging techniques&#xD;
      using low or no radiation dose. Magnetic Resonance Imagery (MRI) with ultrashort echo time&#xD;
      (UTE) pulse sequences with high signal-to-noise and spatial resolution is a promising&#xD;
      alternative for lung nodules imaging.The purpose of the study is to evaluate the value of&#xD;
      DCE-MRI to discriminate of malignant from benign lesions.In this study, the investigators are&#xD;
      going to validate the efficacy of the DCE-MRI for diagnosing early lung cancer by comparing&#xD;
      results of the pre-surgery MRI imaging with the post-surgery pathology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume transfer constant (Ktrans)</measure>
    <time_frame>12 months</time_frame>
    <description>Pharmacokinetic parameters will be estimated by fitting a pharmacokinetic model to the actual time-intensity curves obtained from the DCE-MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the fractional volume of extravascular extracellular space of the target tissue (ve)</measure>
    <time_frame>12 months</time_frame>
    <description>Pharmacokinetic parameters will be estimated by fitting a pharmacokinetic model to the actual time-intensity curves obtained from the DCE-MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the rate constant (kep)</measure>
    <time_frame>12 months</time_frame>
    <description>Pharmacokinetic parameters will be estimated by fitting a pharmacokinetic model to the actual time-intensity curves obtained from the DCE-MRI.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Nodules</condition>
  <arm_group>
    <arm_group_label>MRI scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will undergo 1 DCE-MRI scan before surgery or puncture.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI scan</intervention_name>
    <description>All participants will undergo 1 DCE-MRI scan.</description>
    <arm_group_label>MRI scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ground-glass pulmonary nodules found by CT scan&#xD;
&#xD;
          -  Plan to accept surgery or puncture due to the pulmonary nodules&#xD;
&#xD;
          -  Absence of treatment such as chemotherapy or radiotherapy and biopsy&#xD;
&#xD;
          -  Adequate renal function to tolerate intravenous gadolinium&#xD;
&#xD;
          -  Agree to sign informed consent&#xD;
&#xD;
          -  Able to lie still during DCE-MRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fail to understand or agree to sign informed consent&#xD;
&#xD;
          -  Implanted pacemaker or cardiac defibrillator&#xD;
&#xD;
          -  Contraindications to undergoing MRI&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qianfoshan Hospital</investigator_affiliation>
    <investigator_full_name>Lili Cao</investigator_full_name>
    <investigator_title>investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

